GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer

$538,890
Eduard A. Sergienko · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2025 · CA

Systems Biology of Glycosylation

$538,813
Sriram Neelamegham · State University Of New York At Buffalo · R01 · FY2024 · HL

Targeting PIM-2 Kinase for Improving Cancer Immunotherapy

$538,665
Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2025 · CA

Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer Immunotherapy

$538,330
Hai-Quan Mao · Johns Hopkins University · R01 · FY2024 · CA

Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy

$537,921
Zihai Li · Ohio State University · R01 · FY2023 · CA

Epigenetic and immunologic aspects of neuroendocrine cancers

$537,880
Nitin Roper · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Studies of Materials with Physiological Properties

$537,858
Harvard University · R01 · FY2002 · GM

Chemotherapy and the Bladder Cancer Immune Microenvironment

$537,831
William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA

UCSF Project 1

$537,768
Trever G Bivona · University Of California, San Francisco · U54 · FY2020 · CA

Sustaining Tissue Resident Memory T cells

$537,503
Yina Hsing Huang · Dartmouth College · R01 · FY2022 · CA

Sustaining Tissue Resident Memory T cells

$537,503
Yina Hsing Huang · Dartmouth College · R01 · FY2025 · CA

Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC

$537,336
Rafi Ahmed · Emory University · P50 · FY2022 · CA

Evaluation of Novel Radiation Modifiers

$537,232
Deborah Citrin · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Plk1 as a prognostic biomarker for prostate cancer

$537,065
Xiaoqi Liu · University Of Kentucky · R01 · FY2023 · CA

Plk1 as a prognostic biomarker for prostate cancer

$537,065
Xiaoqi Liu · University Of Kentucky · R01 · FY2022 · CA

Targeting myeloid suppression to enhance anti-tumor immunity in breast cancer

$536,866
Evanthia Theodosiou Roussos Torres · University Of Southern California · R01 · FY2024 · CA

Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer

$536,764
Naoto T Ueno · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Functional and Therapeutic Significance of PLK4 in Melanoma

$536,631
Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2023 · CA

Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation

$536,602
Dmitriy Zamarin · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA

Fractionated photoimmunotherapy to harness low-dose immunostimulation in ovarian cancer

$536,528
Bryan Quilty Spring · Northeastern University · U01 · FY2025 · CA

Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment

$536,018
Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

Role of PI3Kgamma in Tumor Progression and Metastasis

$535,870
Judith A. Varner · University Of California, San Diego · R01 · FY2023 · CA

Role of PI3Kgamma in Tumor Progression and Metastasis

$535,870
Judith A. Varner · University Of California, San Diego · R01 · FY2025 · CA

Investigating a new vulnerability in oral squamous cell carcinoma

$535,846
Christine M Eischen · Thomas Jefferson University · R01 · FY2023 · DE

Project 1- Elucidating oncogenic KRAS in PDAC cell signaling, resistance and immunity

$535,816
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2022 · CA